Syngene International’s share price tanked 13.22% to an intra-day low of Rs 650.05 on the National Stock Exchange after its standalone net profit for the reporting quarter of FY25 fell 8.11% to Rs 174.40 crore from Rs 189.80 crore in Q4FY24.
Its earnings per share ( EPS) has declined to Rs 4.34 for the quarter ending March 31, 2025, as against Rs 4.73 in the corresponding quarter of the previous financial year.
However, the company’s revenue stood at Rs 948.40 crore in March 2025, a growth of 9.68% compared with Rs 864.70 crore in Q4FY24. Its operating profit or EBITDA (earnings before interest, tax, depreciation, and amortisation) stands at Rs 328.40 crore in the last quarter of the fiscal year 2024-25, an increase of 4.39% YoY against Rs 314.60 crore in Q4FY24.
Also, the company’s board recommended a final dividend of Re 1.25 per equity share of face value Rs 10 for the financial year 2024- 25. The record date is fixed as Friday, June 27, 2025, for the payment of the dividend. The dividend will be paid within 30 days from the date of shareholders’ approval.
Peter Bains, Managing Director and CEO, said, “The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market.”
“We expect business momentum to continue with a pipeline build in both small and large molecules, supported by new pilot programs and the conversion of existing pilots in discovery services,” Bains added.
Syngene International stock performance
The stock price of Syngene International has fallen more than 10% in the last five trading days. The stock has declined 9% in the past one month and erased more than 25% of investors’ wealth in the previous six months. The share price of Syngene International has corrected 5.6% in the past one year.